Login to Your Account

NeuroSearch Falls as Troubled Huntexil Raises Safety Concern

By Cormac Sheridan
Staff Writer

Wednesday, May 30, 2012
NeuroSearch A/S's task of securing backing for an additional Phase III trial of its Huntington's disease drug, Huntexil (pridopidine), has gotten a bit more difficult, following the release of data from a multiple-ascending-dose trial indicating that the compound causes QT interval prolongation in healthy volunteers.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription